12:00 AM
Jul 09, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Ozoralizumab: Extension study data

Data from a 48-week, open-label extension study in 231 evaluable patients who completed 1 of 2 double-blind, 16-week Phase II trials showed that ozoralizumab given every 4 weeks led an ACR20 response rate of 84.4% at week 48 compared to 47.4% at baseline of the extension study. At week 48, ACR50 and ACR70 response rates were 63.5% and 32.5%, respectively, compared to 23.7% and 9.8% at baseline of the extension study. Additionally, 38% of patients achieved DAS28 remission at week 48 and 97% of patients had a EULAR response of...

Read the full 426 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >